Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 64

1.
2.
3.

Dendritic cell gene therapy.

Onaitis M, Kalady MF, Pruitt S, Tyler DS.

Surg Oncol Clin N Am. 2002 Jul;11(3):645-60. Review.

PMID:
12487060
4.

Cutaneous T cell lymphoma: the helping hand of dendritic cells.

Edelson RL.

Ann N Y Acad Sci. 2001 Sep;941:1-11. Review.

PMID:
11594563
5.

Membrane structures involved in auto-tumor recognition.

Vánky F.

Biochim Biophys Acta. 1986 Dec 17;865(3):253-65. Review.

PMID:
3539197
6.

Recent advances of dendritic cells (DCs)-based immunotherapy for malignant gliomas.

Cho DY, Lin SZ, Yang WK, Hsu DM, Lee HC, Lee WY, Liu SP.

Cell Transplant. 2009;18(9):977-83. doi: 10.3727/096368909X12483162196962. Epub 2009 May 13. Review.

PMID:
19523342
7.

Dendritic cell-based combined immunotherapy with autologous tumor-pulsed dendritic cell vaccine and activated T cells for cancer patients: rationale, current progress, and perspectives.

Morisaki T, Matsumoto K, Onishi H, Kuroki H, Baba E, Tasaki A, Kubo M, Nakamura M, Inaba S, Yamaguchi K, Tanaka M, Katano M.

Hum Cell. 2003 Dec;16(4):175-82. Review.

PMID:
15147037
8.

Immunotherapy of multiple myeloma.

Ruffini PA, Kwak LW.

Semin Hematol. 2001 Jul;38(3):260-7. Review.

PMID:
11486314
9.

Alternative pathways of cell death to circumvent pleiotropic resistance in myeloma cells: role of cytotoxic T-lymphocytes.

Shtil AA, Turner JG, Dalton WS, Yu H.

Leuk Lymphoma. 2000 Jun;38(1-2):59-70. Review.

PMID:
10811448
10.

A comparison of the cytolytic properties of murine primary CD8+ cytotoxic T lymphocytes and cloned cytotoxic T cell lines.

Nagler-Anderson C, Allbritton NL, Verret CR, Eisen HN.

Immunol Rev. 1988 Mar;103:111-25. Review.

PMID:
3134291
11.

Presentation of tumor antigens.

Hart DN, Schultze JL, Stewart AK.

Semin Hematol. 1999 Jan;36(1 Suppl 3):21-5. Review.

PMID:
9989485
12.

Tumor cell lysates as immunogenic sources for cancer vaccine design.

González FE, Gleisner A, Falcón-Beas F, Osorio F, López MN, Salazar-Onfray F.

Hum Vaccin Immunother. 2014;10(11):3261-9. doi: 10.4161/21645515.2014.982996. Review.

13.

Identification of human idiotype-specific T cells in lymphoma and myeloma.

Weng J, Neelapu SS, Woo AF, Kwak LW.

Curr Top Microbiol Immunol. 2011;344:193-210. doi: 10.1007/82_2010_70. Review. Erratum in: Curr Top Microbiol Immunol. 2011;344:299.

PMID:
20549471
14.

[Role of CTL in liver injury of patients with HCV infection].

Hiroishi K, Matsumura T, Imawari M.

Nihon Rinsho. 2004 Jul;62 Suppl 7(Pt 1):159-63. Review. Japanese. No abstract available.

PMID:
15359785
15.

Immunotherapy using dendritic cells against multiple myeloma: how to improve?

Nguyen-Pham TN, Lee YK, Kim HJ, Lee JJ.

Clin Dev Immunol. 2012;2012:397648. doi: 10.1155/2012/397648. Epub 2012 Mar 15. Review.

16.
17.

Human tumor antigens recognized by T lymphocytes: implications for cancer therapy.

Wang RF, Rosenberg SA.

J Leukoc Biol. 1996 Sep;60(3):296-309. Review.

18.

Novel immunotherapies.

Yi Q.

Cancer J. 2009 Nov-Dec;15(6):502-10. doi: 10.1097/PPO.0b013e3181c51f0d. Review.

19.

Immunoregulation of murine and human myeloma.

Hoover RG, Kornbluth J.

Hematol Oncol Clin North Am. 1992 Apr;6(2):407-24. Review.

PMID:
1582982
20.

Immunotherapy of cancer using dendritic cells.

Morse MA, Lyerly HK.

Cytokines Cell Mol Ther. 1998 Mar;4(1):35-44. Review.

PMID:
9557215
Items per page

Supplemental Content

Write to the Help Desk